RESEARCH
Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. Tasman Oncology Research is a well-resourced and well-published clinical trials unit; with a team of five clinical trial-coordinators and two data entry staff with their their own dedicated suite next to the day infusion unit.
CLINICAL TRIALS
Why do we participate in clinical trials?
Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. All trial related consultations and procedures are provided at no cost to the patient. All research conducted by the Tasman Oncology Research is conducted in accordance with applicable regulatory requirements and the internationally recognised standards of Good Clinical Practice.
Through our close partnerships with clinical research organisations, we coordinate a number of Phase One, Two and Three multi-site international clinical trials which are outlined on the Current Clinical Trials page
If you would like more information regarding clinical trial opportunities, please speak with your doctor or one of our research coordinators. The coordinators can be reached directly on (07) 5613 2484, or research@tasmanhealthcare.com.au.
RESEARCH FACILITIES
Tasman Oncology Research brings together an experienced team of research coordinators, nurses, data managers and scientists to support an advanced clinical trial unit.
Our clinical trials unit is staffed by a highly qualified group of research coordinators who are certified in Good Clinical Practice through ARCS Australia and also hold IATA certification for the transportation of dangerous goods. All coordinators have extensive experience using IVRS/IWRS and eCRF systems. We have a dedicated Quality Manager on team ensuring compliance with ICH-GCP guidelines, TGA regulations, sponsor requirements, protocol requirements and Tasman Health Care SOPs. We have a strong working relationship with Bellberry HREC for efficient study start-up timelines and lead site responsibilities.
Staff are familiar and have up-to-date training in several eCRF platforms including InForm, Medidata RAVE, Oracle RDC and eClinical OS. They are collectively experienced in using patient electronic diaries and imaging transfer software including AGMedNet and Bioclinica.
In addition, the research coordinators have laboratory experience and are competent in all aspects of specimen collection, preparation, handling and shipping.
Tasman Oncology Research views continual education and training as a key investment strategy. Therefore we ensure staff are qualified to perform procedures through ongoing training and professional development. All investigators, sub-investigators and clinical research staff attend both internal and external compulsory training, as well as undertaking further education specific to the nature of this work.
Our monthly quality meetings monitor the need for training and Clinical Research staff conduct regular in-services on the requirements and conduct of clinical research. In particular the specific requirements of individual studies for staff from other departments involved in the conduct of clinical research.
CURRENTLY RECRUITING CLINICAL TRIALS
Please speak to your treating oncologist or GP to investigate whether there may be any current clinical trials you may be suitable for. The following clinical trials are currently open for recruitment:
CF33-hNIS-002 VAXINIA
This is an open-label, dose-escalation, multi-centre phase I study evaluating the safety of CF33-hNIS (hNIS – human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumours
Trial ID: NCT05346484
Cancer Type: Metastatic ovarian, renal and bladder. Other indications open to sponsor approval. Please contact site for further details.
Status: Open and Recruiting
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | ClinicalTrials.gov
ON-5001 (STING)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cemiplimab in Patients with Advanced Solid Tumors and Lymphomas. (ON-5001)
Trial ID: NCT06022029
Cancer Type: Solid Tumours
Status: Open and Recruitment ON HOLD
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cemiplimab in Patients with Advanced Solid Tumors and Lymphomas. | ClinicalTrials.gov
BioNTech BNT317
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Trial ID: NCT06750185
Cancer Type: Solid Tumours
Status: Open and Recruiting
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | ClinicalTrials.gov
Tyra-300
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)
Trial ID: NCT05544552
Cancer Type: Solid Tumours with FGFR3 mutations
Status: Open, Recruitment ON HOLD
Phase: : A Phase 1/2. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found Study Details | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | ClinicalTrials.gov
KN8701
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF And/or NRAS Mutation-positive Solid Tumors.
Trial ID: NCT04913285
Cancer Type: BRAF And/or NRAS Mutation-positive Solid Tumors.
Status: Open, Recruitment ON HOLD
Phase: A Phase 1/1b. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors | ClinicalTrials.gov
TACTI-004
Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Trial ID: NCT06726265
Cancer Type: Metastatic Non-Small Cell Lung Cancer
Status: Open and Recruiting
Phase: Phase 3. This is testing the treatments among a larger group of participants and compares the investigation treatment to existing treatments for the same cancer.
Who can participate: Further information on inclusion and exclusion can be found
INTerpath-009
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial ID: NCT06623422
Cancer Type: Non small cell lung cancer (Resectable Stage II to IIIB)
Neoadjuvant and adjuvant treatment
Status: Open and Recruiting
Phase: Phase 3. This is testing the treatments among a larger group of participants and compares the investigation treatment to existing treatments for the same cancer.
Who can participate: Further information on inclusion and exclusion can be found
CA238-0001
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Trial ID: NCT06730750
Cancer Type: Colorectal, NSCLC and gastric
Status: Open and Recruiting
Phase: A Phase 1/2a. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | ClinicalTrials.gov
CA238-0001
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Trial ID: NCT06730750
Cancer Type: Colorectal, NSCLC and gastric
Status: Open and Recruiting
Phase: A Phase 1/2a. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | ClinicalTrials.gov
DM001001 (DOMA)
This is a Phase 1, multicenter, openlabel, first-in-human (FIH), doseescalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of DM001 in subjects with advanced solid tumors.
Trial ID: NCT06475937
Cancer Type: CRC, GOJ, gastric
Status: Open and Recruiting
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of DM001 in Patients with Advanced Solid Tumors | ClinicalTrials.gov
CA071-1000 (RECHARGE)
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Trial ID: NCT06764485
Cancer Type: Metastatic Castration-resistant Prostate Cancer
Status: Open and Recruiting
Phase: Phase 3. This is testing the treatments among a larger group of participants and compares the investigation treatment to existing treatments for the same cancer.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | ClinicalTrials.gov
SEACRAFT-2
SEACRAFT-2 is a global, Phase III, open-label, randomized study to assess the efficacy and safety of naporafenib administered with trametinib compared to physician’s choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy) in patients with unresectable or metastatic NRAS mutant melanoma who have progressed on, or are intolerant to, an anti-programmed death-1 ligand 1 (PD 1/L1)-based regimen.
Trial ID: NCT06346067
Cancer Type: NRAS Melanoma
Status: Open, recruitment on hold
Phase: Phase 3. This is testing the treatments among a larger group of participants and compares the investigation treatment to existing treatments for the same cancer.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | ClinicalTrials.gov
Il-believe
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)
Trial ID: NCT05081609
Cancer Type: HER2+ MBC, cervical cancer, melanoma, platinum resistance ovarian cancer
Status: Open and recruiting
Phase: A Phase 1/2. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found
CA238-0001
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Trial ID: NCT06730750
Cancer Type: Colorectal, NSCLC and gastric
Status: Open and Recruiting
Phase: A Phase 1/2a. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | ClinicalTrials.gov
DM001001 (DOMA) (multiple categories: colorectal, renal/gastric, breast/ovarian/cervical)
This is a Phase 1, multicenter, openlabel, first-in-human (FIH), doseescalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of DM001 in subjects with advanced solid tumors.
Trial ID: NCT06475937
Cancer Type: CRC, GOJ, gastric
Status: Open and Recruiting
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of DM001 in Patients with Advanced Solid Tumors | ClinicalTrials.gov
DM001001 (DOMA) (multiple categories: colorectal, renal/gastric, breast/ovarian/cervical)
This is a Phase 1, multicenter, openlabel, first-in-human (FIH), doseescalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of DM001 in subjects with advanced solid tumors.
Trial ID: NCT06475937
Cancer Type: CRC, GOJ, gastric
Status: Open and Recruiting
Phase: Phase 1. This is testing the treatments usually for the first time in humans and involves a small participant group.
Who can participate: Further information on inclusion and exclusion can be found Study Details | A Study of DM001 in Patients with Advanced Solid Tumors | ClinicalTrials.gov
Il-believe
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)
Trial ID: NCT05081609
Cancer Type: HER2+ MBC, cervical cancer, melanoma, platinum resistance ovarian cancer
Status: Open and recruiting
Phase: A Phase 1/2. This is combining phase 1 and 2. Usually testing the treatment in humans for the first time in small groups of participants, expanding to larger groups. The overall aim is to find the best tolerated dose that is safe in humans.
Who can participate: Further information on inclusion and exclusion can be found
Please contact our research rooms on (07) 5613 2484 for further information, or follow the clinicaltrials.gov hyperlink for each particular study.